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A B S T R A C T
We have exploited whole brain microscopy to map the progressive deposition of hyperphosphorylated tau in
intact, cleared mouse brain. We found that the three-dimensional spreading pattern of hyperphosphorylated tau
in the brain of an aging Tau.P301L mouse model did not resemble that observed in AD patients. Injection of
synthetic or patient-derived tau fibrils in the CA1 region resulted in a more faithful spreading pattern. Atlas-
guided volumetric analysis showed a connectome-dependent spreading from the injection site and also revealed
hyperphosphorylated tau deposits beyond the direct anatomical connections. In fibril-injected brains, we also
detected a persistent subpopulation of rod-like and swollen microglia. Furthermore, we showed that the hy-
perphosphorylated tau load could be reduced by intracranial co-administration of, and to a lesser extent, by
repeated systemic dosing with an antibody targeting the microtubule-binding domain of tau. Thus, the combi-
nation of targeted seeding and in toto staging of tau pathology allowed assessing regional vulnerability in a
comprehensive manner, and holds potential as a preclinical drug validation tool.
1. Introduction
Alzheimer's disease (AD) is characterised by a progressive accu-
mulation of amyloid beta peptides (Aß) and of tau protein in the brain
(Masters et al., 2015). While both proteins are present in soluble form
in physiologically conditions, increased concentrations of normal and
aggregation-prone variants are observed in patients. Aggregation re-
sults in the formation of insoluble β-sheet–rich polymers, known as Aß
fibrils and paired helical filaments (PHF), which further accumulate to
amyloid plaques and neurofibrillary tangles (NFT), respectively. While
amyloid plaque accumulation is one of the major hallmarks of AD, its
presence does not correlate well with the extent of neurodegeneration,
nor with the cognitive decline observed in patients (Brier et al., 2016).
Moreover, roughly 30% of cognitively normal elderly show elevated
levels of Aβ in the brain (Chételat et al., 2013). In contrast, accrual of
abnormally hyperphosphorylated tau (further referred to as tau pa-
thology) can be observed prior to the development of amyloid plaques,
and correlates better with cognitive disease manifestations (Braak and
Del Tredici, 2004; Cho et al., 2016; Spires-Jones and Hyman, 2014).
Although subject of active debate, these findings suggests that tau pa-
thology could be an important driver in AD aetiology.
While the triggers for the initial tau hyperphosphorylation and ag-
gregation process remain elusive, tau pathology appears to follow a
stereotypical spreading pattern in the affected brain (Brier et al., 2016).
In AD patients, tau pathology starts in the locus coeruleus, and pro-
gresses to the transentorhinal region, the limbic areas, the temporal
lobe and the insular cortex, to finally reach all other isocortical areas
(Brettschneider et al., 2015). To better understand this process, efforts
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have been made to mimic tau pathology in mice using inducible
transgenes (De Calignon et al., 2012) or tau fibril seeding (Guo et al.,
2016; Iba et al., 2013, 2015; Peeraer et al., 2015). As yet, work that
focused on the spatiotemporal evolution of tau pathology has been
performed on sectioned brain tissue. This approach is labour-intensive
and time-consuming. Moreover, the destructive nature of sectioning
leads to loss of material (thus reducing sensitivity) and complicates
downstream standardisation and analytical procedures, such as brain
atlas mapping (Barbier et al., 2017). Hence, there is a need for non-
destructive methods that allow high-resolution imaging of the intact
brain. With the advent of brain clearing and light-sheet microscopy, in
toto imaging of the brain at cellular resolution has become feasible
(Renier et al., 2016; Richardson and Lichtman, 2015). We have now
optimized this technology for the visualisation and quantification of tau
pathology in intact Tau.P301L mouse hemibrain. 3D atlas mapping and
regional analysis revealed that stereotactic injection with synthetic or
patient-derived tau fibrils induced a tau pathology pattern that re-
sembled that of AD patients, and which was associated with a specific
microglial subpopulation. By co-administration of a microtubule-
binding domain targeting antibody, we also showed its potential for
therapeutic intervention studies.
2. Materials and methods
2.1. Transgenic animals
Pathology progression was assessed in Tau.P301L (Terwel et al.,
2005), Tau.P301S (Allen et al., 2002), 3xTG mice (Oddo et al., 2003)
(Table S1). For injection studies, Tau.P301L were used at the age of
90 ± 5 days. All mice were maintained on a 12 h light/dark cycle, with
food and water supplied ad libitum and with cage enrichment. Animals
used in injection studies were single housed and randomised per
treatment group, while non-injected animals were group housed. All
experiments were performed in accordance with the principles of la-
boratory animal care and protocols approved under ECD files 2014–53,
2017–92 (University of Antwerp) and 628-Tau Spread (Janssen Phar-
maceutica). Reporting was done following the ARRIVE guidelines
(Kilkenny et al., 2013).
2.2. Tau fibrils
A myc-tagged, truncated form of human P301L tau protein con-
taining only the four microtubule-binding repeats (K18) was expressed
in bacteria (Tebu-bio). K18 fragments (1mg/ml) were incubated at
37 °C for 5 days in the presence of 133 μM heparin (MP Biomedicals).
The mixture was centrifuged at 184.000 x g for 1 h, after which the
pellet was resuspended in ammonium acetate buffer or PBS (Table S1)
at 5 μg/μl (pH 7.0) and sonicated (Branson probe sonicator, amplitude
15%, total sonication time was 2min in pulses of 2 s with 10 s interval).
K18 fibrils were confirmed by native PAGE and by their potency to
induce tau aggregation in cultured cells expressing Tau.P301L (Fig.
S1A, B) (Holmes et al., 2014).
Enriched paired helical fragments (ePHFs) were purified from post-
mortem brain tissue of a histopathologically confirmed AD patient
(Greenberg and Davies, 1990). Typically, 5 g of tissue from the frontal
cortex were homogenised in 10 volumes of cold buffer H (10mM Tris,
800mM NaCl, 1 mM EGTA, 10% sucrose, pH 7.4) using a glass/Teflon
Potter tissue homogenizer (IKA Works, Inc.; Staufen, Germany) at
1.000 rpm. The homogenate was centrifuged at 27.000 g for 20min and
the supernatant was adjusted to a final concentration of 1% (w/v) N-
lauroylsarcosine and 1% (v/v) 2-mercaptoethanol, and incubated for
2 h at 37 °C. The supernatant was centrifuged at 184.000 x g for 90min
at 20 °C, the pellet was washed with PBS and resuspended in 750 μl PBS,
aliquoted and frozen at −80 °C.
2.3. Antibody treatment
PT83, the antibody targeting the microtubule binding domain of
K18 (267KHQPGG277/299HVPG302/329HHKPGG334/361THVPGG366), was
generated in mouse at Janssen Pharmaceutica (Vandermeeren et al.,
2018). Binding of PT83 to K18 monomers and aggregates was con-
firmed (Fig. S1C). A mouse IgG (Centocor CNTO1037) was used as a
control. Four treatment arms were defined: intracranial (i.c.) buffer
(PBS) and intraperitoneal (i.p.) PBS, i.c. K18 with PT83 and i.p. PBS, i.c.
K18 and i.p. PT83, and i.c. K18 with IgG and i.p. IgG. For i.c. admin-
istration, 0.5 μl PT83 (4 μg/ml) or 0.5 μl buffer was administered to-
gether with 1.5 μl tau fibrils (5 μg/ml), thus keeping a total injected
volume of 2 μl. Repeated i.p. PT83 administration was done at 20mg
per kg bodyweight 4 times in the week preceding injection, followed by
bi-weekly injections in the subsequent 3 weeks until sacrifice. All ani-
mals from this experiment were treated in parallel.
2.4. Stereotactic injection
Tau.P301L mice were deeply anaesthetised with isoflurane (2% in
36% oxygen) and fixed in a stereotactic frame (Neurostar). To correctly
position the head, a tolerance was used in the dorsal-ventral (DV) axis
with ΔDV(Bregma-Lambda) < 0.1mm and ΔDV(ML
Bregma±2) < 0.2mm. Dipodolor (0.25mg/kg; Janssen-Cilag) was
administered via subcutaneous injection, and Xylocaine (AstraZeneca)
was locally applied on the skull. A 30G syringe (Hamilton) was used for
injecting 2 μl in the right hemisphere at a speed of 0.25 μl/min at the
selected coordinates: anterior-posterior −1.83, medial-lateral +1.29
from Bregma, and dorsal-ventral +1.7 from the dura. Body weight was
monitored before and weekly after injection, and no differences were
observed between treatment and control groups for all injection ex-
periments (not shown). Injection with 1.5 μl adeno associated virus
(AAV) that expressed a free-floating green-fluorescent protein (GFP)
under control of neuronal synapsin-1 promoter (pAAV-SEWB) was done
with the same protocol to visualize the connectome of the injection site.
2.5. Clearing and fluorescent labelling
Animals were deeply anaesthetised by intraperitoneal injection
(Nembutal, 150mg/kg), following transcardial perfusion with hepar-
inised PBS (Sigma H3393-50KU; 10 U/ml; 5min) and 4% paraf-
ormaldehyde (Affymetrix USB. J19943; 5min) at 2ml/min. Brains
were dissected, hemisected and post-fixed overnight in 4% PFA at 4 °C,
followed by a PBS wash (3× 15min) and storage in PBS with 0.1%
NaN3 at 4 °C until further processing.
We optimized a microscopy approach to visualize tau pathology in
cleared mouse hemibrain (Fig. S2). Validation of the clearing and la-
belling protocol is described in the supplemental methods and figures
(Figs. S3, S4; Supplementary Movie S1). Fluorescent labelling and
clearing of brain hemispheres were done based on the iDISCO+ pro-
tocol for all brains, except for GFP-labelled brains, which were cleared
with uDISCO to preserve the GFP signal without additional post-hoc
fluorescent labelling (Pan et al., 2016; Renier et al., 2016). Hyper-
phosphorylated tau was specifically detected using an AT8 antibody
(pSer202/Thr205/PSer208, produced at Janssen Pharmaceutica). This
antibody was labelled with a near-infrared fluorescent tag (PerkinElmer
VivoTag 680XL) following the manufacturer's protocol prior to label-
ling (9.18 μg/ml in 1.8 ml for 7 days per hemisphere), yielding AT8-
680XL. The conformation-sensitive optical probe pentameric formyl
thiophene acetic acid (p-FTAA) was used for selective staining of pro-
tein aggregates (30 μM in 1.8 ml for 1 day per hemisphere) (Åslund
et al., 2009). In case of microglial assessment, brains were mounted in a
custom-made slicing tool for sectioning 4mm thick coronal slices
around the injection spot. Sections were rehydrated in a reversed me-
thanol series, and incubated with an Iba1 antibody (Wako 019–19741)
for 2 weeks, followed by a secondary Cy3-conjugated goat-anti-rabbit
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antibody (Jackson 111–165-144) at 37 °C.
2.6. Light-sheet microscopy
Validation of the clearing and labelling performance (Fig. S3, Fig.
S4) was done on a custom-built light-sheet microscope equipped with a
AZ100M zoom body (Nikon) and an Orca R2 camera (Hamamatsu).
Images were recorded at a total magnification of 1.32×, which corre-
sponds to a pixel size of 4.92 μm. The z-step was 10 μm. Bidirectional
excitation with a single light-sheet was achieved with 488 nm, 561 nm
and 640 nm lasers. Emission was detected through bandpass filters
(525/50 nm, 609/54 nm) and a far-red long-pass filter respectively (HQ
BrightLine filters from AHF Analysentechnik).
All other cleared brain samples were acquired with an
Ultramicroscope II (Lavision Biotec GmbH), equipped with an Olympus
MVPLAPO 2× (NA 0.50) objective lens and DBE-corrected LV OM
DCC20 dipping cap. Images were recorded with a Neo sCMOS camera
(Andor) at a total magnification of 1.6× and a z-step of 10 μm resulting
in 4 μm2×10 μm voxels. Images from the left and right light sheets
were merged on the fly with a linear blending algorithm. A 488 nm,
561 nm and 640 nm laser with a 525/50 nm, 620/60 nm and 680/
30 nm emission filter were used. Sagittal optical sections were recorded
in a mosaic of two tiles. The exposure time was in the order of 150ms,
resulting in a recording time of ~ 30min per hemisphere for three
channels. Thick Iba1-stained sections were imaged as one 3D stack of
coronal images.
2.7. Image analysis
To analyse AT8-positive, hyperphosphorylated tau deposition in a
region-dependent manner, we developed an image analysis workflow
allowing sequential image reconstruction, registration, segmentation
and analysis, adapted from the Clearmap protocol (Renier et al., 2016)
(Fig. S5A). First, images were stitched using the ImageJ Grid/Collection
Stitching plugin (Preibisch et al., 2009). Next, the autofluorescence
channel was downsampled to the atlas resolution (25 μm3) and aligned
to a 3D autofluorescence reference brain atlas. To improve the regis-
tration accuracy, a population-based autofluorescence template was
generated by averaging over 20 aligned hemispheres and subsequent
mapping to the Allen Brain Atlas using Elastix (Kim et al., 2015; Klein
et al., 2010) (Fig. S5B). The template was then aligned to the individual
autofluorescence images, and the resulting transformation vector set
was used for regional analysis of the AT8 signal. An inverse transfor-
mation was calculated for visualisation and reconstruction of the
hemisected brains, which were visualised as horizontal and coronal
maximum intensity projections (MIPs) or with 3D renders using Voreen
(Meyer-Spradow et al., 2009). Images containing the AT8-680XL sig-
nals were pre-processed by applying a rolling ball background sub-
traction with a radius of 160 μm, and binarised with a user-defined,
fixed threshold. A morphological opening operation was performed on
the binary mask to remove small false-positive spots resulting from
aspecific labelling, which are predominantly visible at the medial sur-
face of the tissue. The autofluorescent channel was masked to delineate
the contours of the sample, which were subsequently eroded using a
minimum filter (radius 100 μm). This mask was used to remove spur-
ious objects that are detected at the edge of the tissue resulting from
aspecific labelling. Remaining larger non-specific objects in the AT8-
680XL channel originating from blood vessels or from the surface of the
brain tissue, were manually removed. Subsequently, the total number
of AT8-positive voxels for a given hemibrain or brain region volume
was calculated and expressed as a relative AT8 load (AT8 Load %). For
every experiment, stacked bar graphs were drawn in which the AT8
load of individual brain regions was expressed as a fraction of the total
hemibrain AT8 load, and where the AT8 load per condition was nor-
malised to the maximum value (normalised AT8 load).
To visually represent the average AT8 load of one experimental
condition, the registered 3D images of individual hemibrains were
averaged after growing AT8-positive voxels to 50 μm3 spheres. This
growing step was necessary to overcome the loss of voxels after the
down-sampling step that is required for registration. The resulting
average 3D image was subsequently rendered using Voreen (Meyer-
Spradow et al., 2009). To perform voxel-based analysis, AT8-positive
voxels were represented as 375 μm3 spheres to generate heatmaps of
the 3D AT8 distribution. Batch processing and validation tools, such as
cross-sectional prints to assess the stitching, atlas registration and AT8
detection accuracy, were implemented to handle large sample groups.
To register the 4mm coronal section to the atlas, a mask was used to
limit the registration of the section to the corresponding region in the
atlas template. Detection of Iba1 positive structures was done using the
same pipeline, but with modified parameters for the consecutive image
filters, i.e., rolling-ball background subtraction (radius 400 μm), median
filtering (radius 12 μm), and user-defined threshold. To avoid false-
positive detection strongly labelled edges were manually removed. In
correspondence with the calculation of AT8 load, the total number of
Iba1-positive voxels for a given brain region was calculated and ex-
pressed as a fraction of the total hemibrain Iba1 load. The Iba1 load per
condition was then normalised to the maximum value (normalised Iba1
load).
2.8. Statistics
Measurements were represented as means with standard error of
means (SEM) in bar charts. Considering the limited number of biolo-
gical replicates, non-parametric testing was performed. In non-injected
Tau.P301L mice, a Kruskal-Wallis test with post-hoc Dunn tests was
used to determine whether there was an increase in absolute AT8 load
compared to the 6M time point with a Holm–Bonferroni correction for
multiple testing. For K18 and ePHF-injected mice, the Mann-Witney U
test and Holm–Bonferroni correction was used to compare the AT8 load
to buffer controls. For Iba1, the Mann-Witney U test and
Holm–Bonferroni correction was used to compare the Iba1 load in in-
jected vs. non-injected controls. To control for multiple comparisons
across brain subregions, p-values were corrected to q-values with a
false-discovery rate of 10% using the Benjamin-Hochberg procedure
and significant q-values were indicated on the tile plot as dots
(Benjamini and Hochberg, 1995). Considering the larger number of
biological replicates in the PT83 experiment, analysis of variance
(ANOVA) with post-hoc Dunnett's tests was performed using K18+ IgG
(i.c.) as the control. A Shapiro-Wilks test confirmed that the data were
normally distributed, and a Levene's test confirmed that the variance
was not significantly different between treatment groups. Voxel-based
analysis was performed for K18 samples with a p-value cut-off of 5%.
Statistical differences were indicated when p-values whereby:
0.05 > p > 0.01 (*), 0.01 > p > 0.001 (**), and p < 0.001 (***).
3. Results
3.1. In toto microscopy reveals region-specific tau pathology in aging
Tau.P301L mice
To benchmark the whole-brain microscopy approach, we quantified
the evolution of tau pathology (measured as the number of AT8-positive
voxels and therefore further referred to as AT8 load) in non-injected
Tau.P301L mice between the age of 6 and 9months. In line with earlier
findings (Terwel et al., 2005), a progressive increase in the total AT8
load was observed with age in both brain hemispheres (Fig. 1A, B; Fig.
S6A). At 6months of age, AT8 positivity was limited to the brainstem,
cortex and cerebellum, including the cerebellar granular cell layer
(Fig. 1C). At the cellular level, AT8 signal was found in both the so-
matodendritic compartments of neurons as well as in the neuropil
(Fig. 1C). By the age of 9months, additional regions that initially had
no detectable AT8 signal, such as the hypothalamus, cerebral nuclei and
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hippocampus, displayed AT8 load as well (Fig. 1D). Thus, we conclude
that in toto microscopy can be used to quantify tau pathology at the
cellular level in a brain region-dependent manner and this at different
stages of disease development.
3.2. K18 injection triggers AD-like tau pathology in Tau.P301L mice
With no AT8 signal in the forebrain, and a disproportionally large
amount of AT8 signal in the cerebellum and brainstem, the staining
pattern observed in Tau.P301L mice differs substantially from that of
AD patients. Moreover, despite the progressive development of tau
pathology in transgenic mice, it is impossible to determine whether it
results from hyperphosphorylated tau spreading from the initial, more
vulnerable sites, or rather from regional differences in cell-autonomous
build-up of hyperphosphorylated tau. To directly interrogate the spa-
tiotemporal spreading of hyperphosphorylated tau in a targeted
manner, we therefore injected young (3months) Tau.P301L mice with
K18 fibrils in CA1 of the hippocampus (Peeraer et al., 2015). The choice
for this time point was motivated by the desire to have a time window
in which endogenous tau pathology would remain limited. Whereas
buffer-injected, age-matched control mice displayed negligible amounts
of AT8 load, a progressive increase in total AT8 load was observed in
K18-injected animals over a period of 84 days post-injection (DPI)
(Fig. 2A, B; Supplementary Movie S2). To confirm that the K18 injec-
tion induced multiple features of tau pathology – and not solely AT8
reactivity – we verified the presence of hyperphosphorylated tau in
PHFs with an AT100 antibody, as well as the presence of protein ag-
gregates using the ß-sheet selective oligothiophene dye p-FTAA, which
binds both PHFs and NFTs (Åslund et al., 2009; Zheng-Fischhöfer et al.,
1998) (Fig. S7). Of note, the AT8 staining pattern on sections (Fig. S7)
was comparable to in silico generated slices (Fig. 2C), indicating that the
clearing process did not dramatically affect the distribution of
hyperphosphorylated tau.
As early as 7 DPI, a significant increase in AT8 load was quantified
in the hippocampus and isocortex of both ipsi- and contralateral side
(Fig. 2B, C). A more resolved spatial analysis revealed that at this early
time point, AT8 signal was also already present in distal regions such as
the entorhinal area, auditory cortex, somatosensory cortex, and the
thalamus (Fig. 2D; list of brain region abbreviations in Table S2). At 14
DPI, specific regions that were not yet affected at 7 DPI, including the
hypothalamus, cerebral nuclei and the ipsilateral thalamus, were found
positive for AT8. While the hippocampal AT8 load did not increase any
further at the ipsilateral side at 21 DPI, all other contra- and ipsilateral
regions continued to accumulate (AT8-positive) hyperphosphorylated
tau up to 84 DPI. Of note, those regions (cerebellum, medulla, pons)
that were found severely affected in older (8–9months) non-injected
Tau.P301L animals (Fig. 1), remained AT8-negative up to 84 DPI.
CA1 becomes affected at Braak stage II in AD (Braak and Braak,
1991). To find out to what extent tau pathology development would
differ upon targeting a region that becomes affected at an even earlier
stage, we also injected K18 in the afferent entorhinal area (ENT), a
Braak stage I region (Fig. S8). Despite similarities in the spreading
pattern, we observed injection site-specific differences. For example,
the claustrum (CLA) and endopiriform nucleus (EP) were more affected
upon ENT injection, whereas the contralateral cornu ammonis (CA) and
thalamus (TH) were specifically more affected upon CA1 injection. Yet,
despite these quantitative differences, the typical regions that become
affected in AD patients (e.g. rhinal area, hippocampus, subiculum,
thalamus and cortical association area's) were found AT8-positive in
both conditions. This indicates that targeted seeding in early Braak
stage regions induces a spatiotemporal spreading pattern of hyper-
phosphorylated tau that resembles more closely that observed in human
AD patients, when compared to non-injected, aged Tau.P301L mice.
Fig. 1. Region-specific tau pathology in aging Tau.P301L mice. A. 3D rendered views of the average AT8 load in Tau.P301L mouse brain as a function of age; B.
Regional analysis of AT8 load per age group. Bars show AT8 load (mean ± SEM) normalised to the maximum level (9M, L); C. Atlas-transformed image of a 6-
months-old Tau.P301L mouse brain with local maximum-intensity-projected insets showing staining in the neuronal soma, axons (red arrowheads) and the neuropil
(red arrows) of cortical and brainstem neurons. AT8 staining is also present in the granular cell layer (red arrow) of the cerebellum; D. Atlas-transformed image of a 9-
months-old Tau.P301L mouse with insets showing AT8 staining in the hypothalamus, cerebral nuclei and hippocampus. Number of biological replicates: 6 M (n=3),
7M (n=2), 8M (n=6), and 9M (n= 6). A representative set of biological replicates is shown in Fig. S6A.
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3.3. K18 injection induces a specific microglial response
Increasing evidence suggests that microglia contribute to the pro-
gression of tau pathology (Perea et al., 2018). Hence, we evaluated the
microglial response to K18 injection. To this end, an additional ex-
periment was performed in which a mouse cohort was investigated at
25, 74 and 119 DPI to observe both early and chronic microgliosis on
induced tau pathology. Hemispheres were first labelled with AT8 and
subsequently trimmed to 4mm blocks surrounding the injection site
and rehydrated for microglial labelling with an Iba1 antibody (Fig. 3A).
Although the injection itself triggered strong microgliosis (as detected
by Iba1 reactivity) along the injection tract in both K18-injected ani-
mals and buffer controls, a significantly stronger Iba1 load was found in
the ipsilateral hemisphere of K18-injected mice at 25 DPI. The
Fig. 2. K18-induced tau pathology in Tau.P301L mice. A. 3D rendered views of the average AT8 load in K18-injected Tau.P301L mouse brains as a function of
injection time (DPI); B. Regional analysis of AT8 load over time. Bars show AT8 load (mean ± SEM), normalised to the maximum load (9M, R); C. Atlas-transformed
data shown with an inverted look-up-table. Insets show the AT8 positive staining in the ipsi- and contralateral hippocampus and cortex (red arrows) on the raw
images; D. Tile plot showing detailed spatiotemporal fingerprint of AT8 load in K18-injected animals. The values were square root transformed to compress the
dynamic range. Dots represent regions that are significantly different from age-matched buffer controls after FDR correction. A representative set of biological
replicates is shown in Fig. S6B, staining for other tau pathology markers are shown in Fig. S7, and brain abbreviations are listed in Table S2. The number of biological
replicates is n≥4 (Table S1).
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accumulation of Iba1-positive cells around the injection tract, the
corpus callosum and hippocampal formation, was still present at 74
DPI, but decreased significantly at 119 DPI (Fig. 3B, C). In contrast, AT8
load increased from 25 DPI to 74 DPI and remained high at 119 DPI
(Fig. S9). This indicates that the microglial recruitment was not solely
determined by the presence of hyperphosphorylated tau deposits. In-
triguingly, we observed a subpopulation of microglia with swollen cell
body and/or rod-like phenotype in K18-injected animals (Fig. S10A).
This subpopulation was observed to a far lesser extent in buffer and
non-injected controls and persisted up to 119 DPI. While the unusually
large soma of these cells often resided in the vicinity of AT8-positive
neurons, they did not colocalise per se (Fig. S10B). TMEM119 staining
confirmed the microglial nature of these cells, whereas positivity for
CD11B and F4/80-positive suggested they represent a subtype of re-
active microglia (Fig. S10C). While the injection also promoted astro-
gliosis around the injection tract (as detected by increased GFAP re-
activity), we did not observe changes in astrocyte abundance at the
contralateral side between treatment groups at 119 DPI (Fig. S10D).
Thus, we conclude that K18 injection triggers a transient accumulation
of Iba1-positive microglia that extends up to 70 DPI, especially around
the injection tract, but also recruits rod-like and swollen microglia
which persist at least up to 119 DPI.
3.4. K18-induced tau pathology follows anatomical connections
Although the AT8 load developed in and proximal to the injection
site, distally connected brain regions, including the ipsilateral
entorhinal area, hypothalamic regions and the contralateral brain re-
gions were affected as well (Fig. 4A). Conversely, some proximal sites,
such as the ipsilateral dentate gyrus, were only affected at 14 DPI
(Fig. 2D). This indicates that regional accrual of hyperphosphorylated
tau is not solely determined by the distance to the injection site. To
investigate whether this differential vulnerability was determined by
anatomical connections in the brain, we compared the observed AT8
distribution after K18 injection with GFP patterns obtained by injecting
a pAAV-SEWB vector at the exact same coordinates in CA1 (Fig. 4A, B).
At 21 DPI, there was a high correlation between both markers (Pearson
correlation 0.69; Fig. 4C). Distal regions that showed high AT8 load,
such as the entorhinal area and hypothalamus, also showed high GFP
levels, while a proximal region such as the ipsilateral dentate gyrus was
low for both markers (Fig. 4C). This shows that many of the affected
regions represent anatomical projections from or to the CA1 injection
site. Furthermore, AT8 staining was observed in both afferent (e.g.,
dentate gyrus, CA3) and efferent regions (e.g., subiculum, entorhinal
area). Since the AT8 antibody does not recognize K18 fibrils (Malia
et al., 2016), this observation points to anterograde and retrograde
spreading of hyperphosphorylated tau. A notable exception was the
absence of AT8 and GFP signal in the locus coeruleus. Importantly, tau
pathology was also evident in regions that do not have direct projec-
tions from or to CA1 as evidenced by lack of GFP signal (the cortical
subplate, pons, and specific subregions of the olfactory areas and cor-
tical regions) (Fig. 4C). This suggests that spreading of hyperpho-
sphorylated tau not only occurs within anatomical projections from the
injection site, but might also be transmitted to secondary regions.
Fig. 3. K18 injection induces a microglial response. A. The left panel shows a 3D rendering of AT8 labelled hemispherere, which was subsequently trimmed (yellow
lines) to a 3mm thick section and labelled for Iba1 (Fig. S2C). The right panel shows a 3D rendering of the Iba1 staining, with insets highlighting the microglial
response surrounding the injection site represented as consecutive 100 μm virtual sections; B. Representative images of treatment groups shows increased Iba1
staining round the injection tract (red arrows), corpus callosum and hippocampus; C. At 119 DPI, Iba1-positive microglia are in the vicinity of AT8-postive neurons of
the hippocampus, and display a rod-like phenotype and swollen cell bodies (yellow arrows); D. Quantification shows a transient accumulation of Iba1-positive cells,
most prominently in the corpus callosum, which largely disappears at 119 DPI. Bars show normalised Iba1 load (mean ± SEM). The number of biological replicates
is n≥4 (Table S1).
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3.5. Injection with ePHFs induces similar spreading patterns as K18
injection
While synthetic K18 fibrils display strong seeding capability in
Tau.P301L mice, they may do so in a way that is different from pa-
thological tau fibrils that naturally develop in the brain of AD patients.
Hence, similar injection experiments were performed with enriched
paired helical fragments (ePHFs) purified from AD brain (Guo et al.,
2016), using extracts from healthy individuals as a control (Fig. 5A, B).
At 28 DPI, minute AT8-positive staining was observed in the axonal
tracts of the alveus of the ipsi- and contralateral hippocampus; this, in
stark contrast with the strong somatic staining observed at the same
timepoint after K18 injection (Fig. 5C). At 84 DPI, however, a sig-
nificant increase in total AT8 load was evident, with strong AT8 accrual
in the hippocampal formation, the cortex and the fibre tracts of both
hemispheres (Fig. 5C). Regional analysis of the AT8 load revealed a
strong resemblance with that of the K18-injected mice at 84 DPI
(Pearson correlation 0.75; Fig. 5D). A notable difference with K18-in-
coluated brain was the virtual absence of AT8 load in contralateral
olfactory area and cortical subplate. Thus, although the affected regions
Fig. 4. K18-induced tau pathology follows anatomical connections. A. Composite 3D rendering of the GFP connections after uDISCO clearing and AT8 load from a
representative iDISCO+ cleared brain at 28 DPI. Anatomical connections of the injections site are indicated, including the thalamus (TH), hypothalamus (HY), ispi-
and contralateral entorhinal area (ENT) and the retrosplenial area (RSP); B. The first two columns represent atlas-transformed AT8 virtual slices and segmented
voxels for a 21 DPI K18-injected mouse brain. Virtual slices and segmented voxels of the corresponding GFP data are show in the last two columns; C. Tile plots of
AT8 load after K18 injection at 84 DPI compared to the GFP projection map generated after uDISCO clearing. The regional AT8 load was square root transformed to
compress the dynamic range. The number of biological replicates is 2.
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at this last time point were similar to those associated with K18-induced
tau pathology, the kinetics differed, with AT8 signal predominantly
present in axonal tracts up to 28 DPI, while somatic AT8 load emerged
at 84 DPI.
3.6. Co-administration of PT83 antibody slows down tau pathology
progression
To investigate if K18-induced tau pathology could be blocked, we
performed K18 injection experiments in combination with a micro-
tubule-binding domain targeting antibody (PT83). As proof of concept,
we co-injected the PT83 antibody along with the K18 fibrils. We found a
bilateral reduction in total AT8 load following intracerebral co-
administration (Fig. 6A, Fig. S6D). While only a limited reduction was
found around the injection site, regional analysis revealed a significant
decrease in most other affected brain regions (Fig. 6B). Next, we as-
sessed whether the same antibody could reduce tau pathology devel-
opment in K18 injected Tau.P301L mice upon repeated i.p. dosing.
Although we found a reduction in total AT8 load as compared to con-
trols, this difference was statistically not significant. However, regional
analysis revealed a significant decrease in the contralateral hippo-
campal region after i.p. PT83 administration. This experiment showed
that the seeding effect of K18, and the resulting accrual of hyperpho-
sphorylated tau, can be slowed down using cerebral and, to a lesser
extent, i.p. administration of a therapeutic antibody.
Fig. 5. ePHF injection induces similar spreading patterns as K18. A. 3D renders of average AT8 load in ePHF-injected Tau.P301L mouse brains as a function of
injection time (DPI); B. Regional analysis of AT8 load over time. Bars show AT8 load (mean ± SEM) normalised to the maximum level (84 DPI, R); C. Transformed
atlas of raw images shows AT8-positive staining in axonal fibre tracts at 28 DPI, and somatic staining at 84 DPI. Insets show the accumulation of AT8 signal in the
fibre tracts of ispi- and contralateral alveus of the hippocampus (red arrows) on raw images; D. Sub-regional assessment of AT8 load in ePHF-injected animals, with a
similar heat map of K18-injected animals at 84 DPI as a reference (gray code). The regional AT8 load was square root transformed to compress the dynamic range. No
statistical analysis was performed considering the limited sample size (n=3).
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4. Discussion
To date, tissue sectioning has remained the gold standard for doc-
umenting neuropathological hallmarks in transgenic mouse brain. We
have now performed a non-destructive, comprehensive staging of AT8-
reactive tau pathology by exploiting tissue clearing and whole brain
microscopy. Although visualisation of hyperphosphorylated tau has
been achieved in cleared mouse brain before (Fu et al., 2016; Liebmann
et al., 2016), we have now introduced a systematic and scalable ap-
proach for atlas-guided, regional analysis of tau pathology progression.
Using this approach, we validated the age-dependent distribution pat-
tern of tau pathology in Tau.P301L mice. Despite strong correspon-
dence with previously documented patterns (Terwel et al., 2005), our
analysis also revealed additional regions including the hypothalamus,
cerebral nuclei and hippocampus. While this underlies the sensitivity of
our approach, we can not establish whether the presence of AT8 signal
in these regions is a result of cell autonomous development, or a result
of tau spreading from previously affected regions in this model.
To study the spreading of tau pathology as observed in AD patients,
we performed intracerebral injections with tau fibrils in the CA1 region
of Tau.P301L mice. Although ePHF was recently demonstrated to seed
hyperphosphorylated tau accrual in wild-type mice (in contrast with
K18) (Guo et al., 2016), we have opted for the Tau.P301L background
to allow for a direct comparison of between both seeds. The injection
was done in 3months-old mice based on previous literature (Peeraer
et al., 2015), allowing longitudinal follow-up up to 3–4months post
injection, before overt AT8 load develops as a result of the transgenic
background of this model. While the concentration of injected K18 and
ePHF preparations was based on previous studies (Peeraer et al., 2015;
Vandermeeren et al., 2018), it should be noted that those are higher
than the values of tau reported in interstitial fluid (Sato et al., 2018).
Although the concentration of tau seeds in human interstitial fluid of
AD patients is unknown, it might be important to take this into account
as it may determine the neuronal uptake mechanism of tau (Evans
et al., 2018).
The CA1 region shows abundant tau pathology in AD at an early
stage (i.e., Braak stage II) (Braak et al., 2006), and stereotactic injec-
tions in this region were previously validated (Peeraer et al., 2015).
While it would have been relevant to target the first known region in-
volved in AD, i.e., the locus coeruleus, this is technically more chal-
lenging due to the small size of the brain nucleus (Iba et al., 2015).
Moreover, targeting a structure located this deep within the brain
(dorsal-ventral +3.65mm) would also affect many more other brain
sites along the injection tract, potentially decreasing the regional con-
finement of initial tau seeding.
In line with earlier findings with the same K18 model (Peeraer et al.,
Fig. 6. PT83 administration reduces tau pathology in K18-injected animals. A. Regional AT8 load distribution in animals at 21 DPI in combination with i.c. and
repeated i.p. PT83 administration. While total AT8 load was significantly decreased after i.c. administration, only the hippocampal region was significantly decreased
after i.p. administration. Bars show mean ± SEM AT8 load normalised to the maximum level (K18+ IgG (IC), R); B. Atlas-transformed coronal sections of a 3D
recording of representative samples of the control and treatment groups. Voxel-based analysis with p-value maps highlight regions that have decreased tau pathology
compared to animals that received a K18 and control IgG. A representative set of biological replicates are shown in Fig. S6D. The number of biological replicates is 15,
except for the PBS control (n=5).
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2015), we found hyperphosphorylated tau accrual in similar regions.
However, in this study, the analysis was limited to only a subset of
larger, ipsilateral regions, whereas we now performed a detailed ana-
lysis of the entire brain. A section-based study in which K18 fibrils were
injected in the hippocampus of Tau.P301S mice showed generally fewer
affected regions (e.g., contralateral cortical regions) and a slower pro-
gression (Iba et al., 2013). In contrast with this study, we found no
hyperphosphorylated tau in the locus coeruleus. Moreover, the GFP
pattern from the injection site did not demonstrate anatomical con-
nections to the locus coeruleus. The latter aligns with published ana-
tomical data of tracer experiments in the CA1 region (e.g., Allen Brain
Mouse Connectivity Experiment 116900714). While differences in
anatomical projection data and regional tau pathology development
may be attributed to the mouse strain and genetic background, it is
plausibly also related to differences in the K18 fibril injection protocol
(i.e. fibril preparation, injected volume and concentration) and the in-
jection site, which was more ventral and posterior in the hippocampus
in the cited study. Therefore, a different population of projecting neu-
rons was targeted, and the propensity of these neurons to develop tau
pathology was different between the transgenic tau mouse models in
both studies. We have also targeted the entorhinal region in this study,
affected earlier in AD. While quantitative differences were observed,
the distribution pattern of hyperphosphorylated tau resembled that of
CA1 seeding. Considering that the ENT directly projects to CA1 and
both regions have shared connections to limbic and cortical structures,
this finding further supports a hypothesis of tau spreading within
anatomical projections in the anterograde and retrograde direction
(Defelipe, 2014; Iba et al., 2015). Nevertheless, marked differences in
affected brain regions between both experiments, indicate that the in-
jection site determines tau pathology progression. The extent with
which this spreading process is mediated by the intrinsic vulnerability
of neurons to develop tau pathology, remains to be elucidated (Walsh
and Selkoe, 2016).
Previous studies have yielded conflicting results regarding tau fibril
injection induced microgliosis (Clavaguera et al., 2009; Peeraer et al.,
2015). Although in our study, both K18 injection and buffer controls
triggered microgliosis around the injection site, we detected a sig-
nificantly higher Iba1 load in the targeted fibre tracts after K18 injec-
tion. Since the decrease in microgliosis over time did not correlate with
a similar drop in hyperphosphorylated tau levels, other factors may
regulate this response. These may include a decrease in the levels of
other pathological tau species, a decrease in the rate of cell death and/
or presence of cell debris, or a compromised microglial function as a
consequence of chronic pathological conditions (Krasemann et al.,
2017; Pan et al., 2011). On the other hand, we also detected a persistent
subpopulation of rod-like and swollen microglia after K18 injection.
This phenotype seems to be specifically associated with pathological
conditions as they have been described in rat after diffuse brain injury,
but also in AD patients and AD mouse models (Bachstetter et al., 2015;
Chen et al., 2016; Sanders et al., 2014; Taylor et al., 2014). Microglia
with swollen cell bodies are considered to be in an activated state (del
Fernández-Arjona et al., 2017), which was confirmed by the presence of
the activation markers CD11B and F4/80. While the function of rod-like
microglia is unclear, this phenotype might mediate processes including
the sealing or splinting damaged neuronal processes, or the protection
of healthy neighbouring cells from injury (Taylor et al., 2014).
We demonstrated that tau pathology development after K18 injec-
tion closely matches with both the anterograde and retrograde anato-
mical connections of the injection site (Van Strien et al., 2009). Since it
has been shown that K18 fibrils do not diffuse to remote regions, such
as the contralateral hemisphere (Peeraer et al., 2015), our data suggests
that the presence of hyperphosphorylated tau in connected regions is
due to its intracellular spreading as opposed to a direct distal seeding
effect. Furthermore, the presence of hyperphosphorylated tau outside of
the connectome strengthens the hypothesis of its intercellular trans-
mission. This is corroborated by other studies demonstrating
bidirectional propagation of tau pathology after locus coeruleus injec-
tion, followed by spreading to secondary connected regions (Iba et al.,
2015). While several mechanisms for the induction and the intercellular
spreading of hyperphosphorylated tau have been put forward, regional
vulnerability seems to vary for distinct pathological tau strains (Guo
and Lee, 2014; Kaufman et al., 2016). However, despite different
spreading kinetics between K18 and ePHF seeding, the spatial
spreading patterns were similar, suggesting common seeding properties
for these fibril preparations.
Although tau is an intracellular protein and therefore not an evident
immunization target, several active and passive immunization studies
in tauopathy mice previously showed an effective decrease in patho-
logical tau load and associated functional deficits (Congdon and
Sigurdsson, 2018). We have shown that the seeding activity of K18 can
be inhibited by co-injection, and to a lesser extent by repeated i.p.
dosing, of PT83. Considering PT83 binds microtubule-binding domain
of tau (Vandermeeren et al., 2018), it is very likely that PT83 directly
inhibits K18 seeding. Although this domain normally functions to sta-
bilise microtubules (Guo et al., 2017), it also contains aggregation-
prone residues and is responsible for pathological tau interactions
(Fitzpatrick et al., 2017; Kontsekova et al., 2014; Mukrasch et al.,
2009). Only a single other study demonstrated this effect in a K18-
seeded mouse model to date using PHF13 (Sankaranarayanan et al.,
2015). This antibody targets pS396 in the c-terminus region of tau, i.e.,
outside the K18 region, and is considered to operate by binding brain-
derived tau. Further studies that directly compare both antibodies, in-
cluding similar seeding and antibody dosing schemes would be valuable
to identify the most effective epitope to inhibit tau pathology devel-
opment. Exactly how passive immunization reduces tau pathology is
poorly understood, but it may be the result of extracellular clearance of
tau via glial activation, intracellular degradation, or by inhibiting tau
interactions thus preventing the seeding effect (Congdon et al., 2013;
Ising et al., 2017; Luo et al., 2015). The ostensible lack of decrease in
AT8 load at the injection site may indicate that the K18-induced tau
pathology is locally saturated, and that the local K18 concentration is
too high for PT83 to block all K18-tau interaction. The limited reduc-
tion in total AT8 load found after repeated i.p. dosing is likely a result of
the limited penetration of PT83 through the tightly regulated blood-
brain-barrier (BBB) (Paul, 2011). However, we could detect a sig-
nificant decrease in the contralateral hippocampal AT8 load after i.p.
dosing, indicating that regional assessment allows more sensitive eva-
luation of therapeutics. Nevertheless, more effective therapeutic de-
livery strategies are needed. Increased bioavailability might be
achieved with small antibody fragments (Krishnaswamy et al., 2014),
by exploiting BBB shuttle mechanisms (Hultqvist et al., 2017), or by
temporary BBB disruption using high-intensity focused ultrasound or by
co-administration with vasoactive or osmotic substances (Marcos-
Contreras et al., 2016; McDannold et al., 2008). Although K18 frag-
ments only represent a truncated version of tau protein, this result
shows that K18 can be targeted by passive immunization. However,
follow-up studies with ePHFs are necessary to demonstrate the trans-
lational value of this approach. Moreover, it would of interest to assess
whether the demonstrated therapeutic effect of PT83 may also have
protective effects on downstream effects of K18, such as glial activation.
In conclusion, the combination of injection experiments with whole-
brain microscopy offers a novel approach to assess the spatiotemporal
dynamics of different tau strains and measure the effects of therapeutic
interventions aiming at slowing down or halting the progression of tau
pathology.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.nbd.2019.03.010.
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